<DOC>
	<DOCNO>NCT01077466</DOCNO>
	<brief_summary>The purpose study study safety efficacy natalizumab treatment primary secondary progressive multiple sclerosis . This do measuring effect treatment inflammation CNS mean osteopontin level cerebrospinal fluid ( CSF ) . Safety measure include physical neurological examination , blood sample MRI measure disease activity .</brief_summary>
	<brief_title>Natalizumab Treatment Progressive Multiple Sclerosis</brief_title>
	<detailed_description>The study include 12 secondary progressive multiple sclerosis patient 12 primary progressive multiple sclerosis patient treatment IV natalizumab 60 week . At baseline week 60 lumbar puncture perform . MRI scan perform baseline week 12 week 60.Safety blood sample collect every 12 week .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Chronic Progressive</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<criteria>Age 19 55 year Progressive disease course multiple sclerosis ( primary secondary ) Duration progressive phase least 1 year Progression &gt; 1 EDSS point last 2 year ( &gt; ½ EDSS point EDSS &gt; 5,5 ) EDSS &lt; /= 6.5 Written inform consent Pregnancy , breastfeed lack anti.conception fertile woman . Attack last month inclusion . Treatment methylprednisolone 3 month inclusion . Treatment interferonbeta , glatirameracetate , immunoglobulin G immunemodulating treatment 3 month prior inclusion . Treatment mitoxantrone , cyclophosphamide , azathioprine strong immunosuppressive drug 6 month prior inclusion . Prior experimental treatment strong immunosuppressive drug treat physician mean influence result trial . Diseases associated immunodeficiency . Treatment anticoagulant aspirin . Current malign disease . Diabetes Mellitus autoimmune disease . Renal insufficiency creatinine &gt; 150 μmol/l . Travel tropical area 3 month prior inclusion . Acute chronic infectious disease , treat physician find relevant ( e.g.hepatitis B virus , hepatitis C virus , HIV ) . Psychiatric disease circumstance may limit patient participation trial . Contraindication MRI scan gadolinium contrast . Known hypersensitivity natalizumab .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Primary Progressive Multiple Sclerosis</keyword>
	<keyword>Secondary Progressive Multiple Sclerosis</keyword>
	<keyword>Natalizumab</keyword>
	<keyword>Treatment</keyword>
	<keyword>Safety</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Cerebrospinal fluid</keyword>
	<keyword>Osteopontin</keyword>
</DOC>